ID: ALA206559

Max Phase: Preclinical

Molecular Formula: C30H35F3N4O6

Molecular Weight: 604.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Nc2ccc(C(F)(F)F)cc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C30H35F3N4O6/c1-5-6-12-22(23(38)25(39)34-18(2)19-10-8-7-9-11-19)36-28(42)43-24-26(40)37(17-29(24,3)4)27(41)35-21-15-13-20(14-16-21)30(31,32)33/h7-11,13-16,18,22,24H,5-6,12,17H2,1-4H3,(H,34,39)(H,35,41)(H,36,42)/t18-,22+,24-/m1/s1

Standard InChI Key:  OWCPERUTCVQATE-RVSNTGDXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 604.63

Molecular Weight (Monoisotopic): 604.2509

AlogP: 5.21

#Rotatable Bonds: 10

Polar Surface Area: 133.91

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.09

CX Basic pKa:

CX LogP: 5.86

CX LogD: 5.86

Aromatic Rings: 2

Heavy Atoms: 43

QED Weighted: 0.32

Np Likeness Score: -0.60

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature